ID   OPRM_HUMAN              Reviewed;         400 AA.
AC   P35372; B0FXJ1; B2R9S7; B8Q1L7; B8Q1L8; B8Q1L9; E7EWZ3; G8XRH6;
AC   G8XRH8; Q12930; Q4VWM1; Q4VWM2; Q4VWM3; Q4VWM4; Q4VWM6; Q4VWX6;
AC   Q5TDA1; Q6UPP1; Q6UQ80; Q7Z2D8; Q86V80; Q8IWW3; Q8IWW4; Q9UCZ4;
AC   Q9UN57;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   12-APR-2017, entry version 173.
DE   RecName: Full=Mu-type opioid receptor;
DE            Short=M-OR-1;
DE            Short=MOR-1;
DE   AltName: Full=Mu opiate receptor;
DE   AltName: Full=Mu opioid receptor;
DE            Short=MOP;
DE            Short=hMOP;
GN   Name=OPRM1; Synonyms=MOR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RC   TISSUE=Brain;
RX   PubMed=7905839; DOI=10.1016/0014-5793(94)80368-4;
RA   Wang J.-B., Johnson P.S., Persico A.M., Hawkins A.L., Griffin C.A.,
RA   Uhl G.R.;
RT   "Human mu opiate receptor. cDNA and genomic clones, pharmacologic
RT   characterization and chromosomal assignment.";
RL   FEBS Lett. 338:217-222(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), VARIANT ASP-40, FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Brain;
RX   PubMed=7957926; DOI=10.1016/0014-5793(94)01129-X;
RA   Bare L.A., Mansson E., Yang D.;
RT   "Expression of two variants of the human mu opioid receptor mRNA in
RT   SK-N-SH cells and human brain.";
RL   FEBS Lett. 354:213-216(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RC   TISSUE=Brain;
RX   PubMed=7891175;
RA   Mestek A. Jr., Hurley J.H., Bye L.S., Campbell A.D., Chen Y., Tian M.,
RA   Liu J., Schulman H., Yu L.;
RT   "The human mu opioid receptor: modulation of functional
RT   desensitization by calcium/calmodulin-dependent protein kinase and
RT   protein kinase C.";
RL   J. Neurosci. 15:2396-2406(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 5), FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=12589820; DOI=10.1016/S0006-291X(03)00089-5;
RA   Pan Y.X., Xu J., Mahurter L., Xu M., Gilbert A.K., Pasternak G.W.;
RT   "Identification and characterization of two new human mu opioid
RT   receptor splice variants, hMOR-1O and hMOR-1X.";
RL   Biochem. Biophys. Res. Commun. 301:1057-1061(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 14), FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=12734358; DOI=10.4049/jimmunol.170.10.5118;
RA   Cadet P., Mantione K.J., Stefano G.B.;
RT   "Molecular identification and functional expression of mu 3, a novel
RT   alternatively spliced variant of the human mu opiate receptor gene.";
RL   J. Immunol. 170:5118-5123(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 4; 6; 7; 8; 9 AND 11).
RX   PubMed=15893644; DOI=10.1016/j.neuroscience.2004.12.033;
RA   Pan L., Xu J., Yu R., Xu M.-M., Pan Y.-X., Pasternak G.W.;
RT   "Identification and characterization of six new alternatively spliced
RT   variants of the human mu opioid receptor gene, Oprm.";
RL   Neuroscience 133:209-220(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 10; 12 AND 13).
RX   PubMed=19077058; DOI=10.1111/j.1471-4159.2008.05833.x;
RA   Xu J., Xu M., Hurd Y.L., Pasternak G.W., Pan Y.X.;
RT   "Isolation and characterization of new exon 11-associated N-terminal
RT   splice variants of the human mu opioid receptor gene.";
RL   J. Neurochem. 108:962-972(2009).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 6 AND 15).
RC   TISSUE=Brain;
RA   Baar C., Kvam T.-M., Rakvag T.T., Kaasa S., Skorpen F.;
RT   "Novel variants of the human mu opioid receptor are generated by
RT   alternative splicing and transcription from different positions in the
RT   OPRM1 gene.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 18).
RA   Xu J., Pasternak G.W., Pan Y.;
RT   "Isolation and expression of alternatively spliced variants encoding
RT   proteins with single transmembrane domain in mu opioid receptor
RT   genes.";
RL   Submitted (DEC-2010) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 12).
RC   TISSUE=Brain;
RX   PubMed=19103668; DOI=10.1093/hmg/ddn439;
RA   Shabalina S.A., Zaykin D.V., Gris P., Ogurtsov A.Y., Gauthier J.,
RA   Shibata K., Tchivileva I.E., Belfer I., Mishra B., Kiselycznyk C.,
RA   Wallace M.R., Staud R., Spiridonov N.A., Max M.B., Goldman D.,
RA   Fillingim R.B., Maixner W., Diatchenko L.;
RT   "Expansion of the human mu-opioid receptor gene architecture: novel
RT   functional variants.";
RL   Hum. Mol. Genet. 18:1037-1051(2009).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-6; ASP-40;
RP   CYS-147; ASP-152; CYS-265 AND ASN-274.
RG   NIEHS SNPs program;
RL   Submitted (NOV-2006) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 6 AND 10).
RA   Xu J., Xu M., Pasternak G.W., Pan Y.;
RT   "Isolation and characterization of two alternatively spliced variants
RT   from the human mu opioid receptor, OPRM1, gene.";
RL   Submitted (AUG-2008) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-20, AND VARIANT VAL-6.
RC   TISSUE=Blood;
RA   Metha S., Glendenning M., Kutlar A., Kutlar F.;
RT   "An homozygous Ala 6 Val (GCC->GTC) mutation was detected on human mu
RT   opioid receptor gene of an African American individual with sickle
RT   cell anemia.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-47.
RX   PubMed=10393893; DOI=10.1073/pnas.96.14.7752;
RA   Uhl G.R., Sora I., Wang Z.;
RT   "The mu opiate receptor as a candidate gene for pain: polymorphisms,
RT   variations in expression, nociception, and opiate responses.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:7752-7755(1999).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 229-374.
RX   PubMed=7488213; DOI=10.1006/bbrc.1995.2709;
RA   Chuang T.K., Killam K.F. Jr., Chuang L.F., Kung H.F., Sheng W.S.,
RA   Chao C.C., Yu L., Chuang R.Y.;
RT   "Mu opioid receptor gene expression in immune cells.";
RL   Biochem. Biophys. Res. Commun. 216:922-930(1995).
RN   [21]
RP   INTERACTION WITH PLD2.
RX   PubMed=12519790; DOI=10.1074/jbc.M206709200;
RA   Koch T., Brandenburg L.O., Schulz S., Liang Y., Klein J., Hollt V.;
RT   "ADP-ribosylation factor-dependent phospholipase D2 activation is
RT   required for agonist-induced mu-opioid receptor endocytosis.";
RL   J. Biol. Chem. 278:9979-9985(2003).
RN   [22]
RP   MUTAGENESIS OF CYS-142 AND CYS-219, FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=10529478; DOI=10.1016/S0169-328X(99)00241-7;
RA   Zhang P., Johnson P.S., Zollner C., Wang W., Wang Z., Montes A.E.,
RA   Seidleck B.K., Blaschak C.J., Surratt C.K.;
RT   "Mutation of human mu opioid receptor extracellular 'disulfide
RT   cysteine' residues alters ligand binding but does not prevent receptor
RT   targeting to the cell plasma membrane.";
RL   Brain Res. Mol. Brain Res. 72:195-204(1999).
RN   [23]
RP   INTERACTION WITH CALMODULIN, AND MUTAGENESIS OF LYS-273.
RX   PubMed=10419536; DOI=10.1074/jbc.274.31.22081;
RA   Wang D., Sadee W., Quillan J.M.;
RT   "Calmodulin binding to G protein-coupling domain of opioid
RT   receptors.";
RL   J. Biol. Chem. 274:22081-22088(1999).
RN   [24]
RP   REVIEW.
RX   PubMed=10836142; DOI=10.1146/annurev.pharmtox.40.1.389;
RA   Law P.Y., Wong Y.H., Loh H.H.;
RT   "Molecular mechanisms and regulation of opioid receptor signaling.";
RL   Annu. Rev. Pharmacol. Toxicol. 40:389-430(2000).
RN   [25]
RP   INTERACTION WITH CALMODULIN, AND MUTAGENESIS OF LYS-273 AND ARG-275.
RX   PubMed=10899953; DOI=10.1046/j.1471-4159.2000.0750763.x;
RA   Wang D., Surratt C.K., Sadee W.;
RT   "Calmodulin regulation of basal and agonist-stimulated G protein
RT   coupling by the mu-opioid receptor (OP(3)) in morphine-pretreated
RT   cell.";
RL   J. Neurochem. 75:763-771(2000).
RN   [26]
RP   RECEPTOR HETEROOLIGOMERIZATION, AND INTERACTION WITH CCR5.
RX   PubMed=12413885; DOI=10.1006/excr.2002.5638;
RA   Suzuki S., Chuang L.F., Yau P., Doi R.H., Chuang R.Y.;
RT   "Interactions of opioid and chemokine receptors: oligomerization of
RT   mu, kappa, and delta with CCR5 on immune cells.";
RL   Exp. Cell Res. 280:192-200(2002).
RN   [27]
RP   COUPLING TO GNAI1 AND GNAI2.
RX   PubMed=12068084; DOI=10.1046/j.1471-4159.2002.00946.x;
RA   Massotte D., Brillet K., Kieffer B., Milligan G.;
RT   "Agonists activate Gi1 alpha or Gi2 alpha fused to the human mu opioid
RT   receptor differently.";
RL   J. Neurochem. 81:1372-1382(2002).
RN   [28]
RP   INTERACTION WITH PPL.
RX   PubMed=12810704; DOI=10.1074/jbc.M305866200;
RA   Feng G.J., Kellett E., Scorer C.A., Wilde J., White J.H., Milligan G.;
RT   "Selective interactions between helix VIII of the human mu-opioid
RT   receptors and the C terminus of periplakin disrupt G protein
RT   activation.";
RL   J. Biol. Chem. 278:33400-33407(2003).
RN   [29]
RP   INTERACTION WITH FLNA.
RX   PubMed=14573758; DOI=10.1124/mol.64.5.1092;
RA   Onoprishvili I., Andria M.L., Kramer H.K., Ancevska-Taneva N.,
RA   Hiller J.M., Simon E.J.;
RT   "Interaction between the mu opioid receptor and filamin A is involved
RT   in receptor regulation and trafficking.";
RL   Mol. Pharmacol. 64:1092-1100(2003).
RN   [30]
RP   HOMOOLIGOMERIZATION, RECEPTOR HETEROOLIGOMERIZATION, AND INTERACTION
RP   WITH OPRD1 AND OPRK1.
RX   PubMed=15778451; DOI=10.1124/mol.104.010272;
RA   Wang D., Sun X., Bohn L.M., Sadee W.;
RT   "Opioid receptor homo- and heterodimerization in living cells by
RT   quantitative bioluminescence resonance energy transfer.";
RL   Mol. Pharmacol. 67:2173-2184(2005).
RN   [31]
RP   HOMOOLIGOMERIZATION.
RX   PubMed=15967873; DOI=10.1124/mol.105.013847;
RA   Pascal G., Milligan G.;
RT   "Functional complementation and the analysis of opioid receptor
RT   homodimerization.";
RL   Mol. Pharmacol. 68:905-915(2005).
RN   [32]
RP   ALTERNATIVE SPLICING (ISOFORMS 16 AND 17), FUNCTION (ISOFORMS 16 AND
RP   17), SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND SUBUNIT.
RX   PubMed=16580639; DOI=10.1016/j.bbrc.2006.03.084;
RA   Choi H.S., Kim C.S., Hwang C.K., Song K.Y., Wang W., Qiu Y., Law P.Y.,
RA   Wei L.N., Loh H.H.;
RT   "The opioid ligand binding of human mu-opioid receptor is modulated by
RT   novel splice variants of the receptor.";
RL   Biochem. Biophys. Res. Commun. 343:1132-1140(2006).
RN   [33]
RP   INTERACTION WITH DNAJB4.
RX   PubMed=16542645; DOI=10.1016/j.brainres.2006.01.125;
RA   Ancevska-Taneva N., Onoprishvili I., Andria M.L., Hiller J.M.,
RA   Simon E.J.;
RT   "A member of the heat shock protein 40 family, hlj1, binds to the
RT   carboxyl tail of the human mu opioid receptor.";
RL   Brain Res. 1081:28-33(2006).
RN   [34]
RP   RECEPTOR HETEROOLIGOMERIZATION, AND INTERACTION WITH NPFFR2.
RX   PubMed=17224450; DOI=10.1074/jbc.M606946200;
RA   Roumy M., Lorenzo C., Mazeres S., Bouchet S., Zajac J.M.,
RA   Mollereau C.;
RT   "Physical association between neuropeptide FF and micro-opioid
RT   receptors as a possible molecular basis for anti-opioid activity.";
RL   J. Biol. Chem. 282:8332-8342(2007).
RN   [35]
RP   REVIEW.
RX   PubMed=19300905; DOI=10.1007/s00018-009-0008-4;
RA   Lopez A., Salome L.;
RT   "Membrane functional organisation and dynamic of mu-opioid
RT   receptors.";
RL   Cell. Mol. Life Sci. 66:2093-2108(2009).
RN   [36]
RP   INTERACTION WITH RANBP9.
RX   PubMed=19788913; DOI=10.1016/j.neulet.2009.09.048;
RA   Talbot J.N., Skifter D.A., Bianchi E., Monaghan D.T., Toews M.L.,
RA   Murrin L.C.;
RT   "Regulation of mu opioid receptor internalization by the scaffold
RT   protein RanBPM.";
RL   Neurosci. Lett. 466:154-158(2009).
RN   [37]
RP   INTERACTION WITH WLS.
RX   PubMed=20214800; DOI=10.1186/1471-2202-11-33;
RA   Jin J., Kittanakom S., Wong V., Reyes B.A., Van Bockstaele E.J.,
RA   Stagljar I., Berrettini W., Levenson R.;
RT   "Interaction of the mu-opioid receptor with GPR177 (Wntless) inhibits
RT   Wnt secretion: potential implications for opioid dependence.";
RL   BMC Neurosci. 11:33-33(2010).
RN   [38]
RP   FUNCTION (ISOFORM 12), AND SUBCELLULAR LOCATION (ISOFORM 12).
RX   PubMed=20525224; DOI=10.1186/1744-8069-6-33;
RA   Gris P., Gauthier J., Cheng P., Gibson D.G., Gris D., Laur O.,
RA   Pierson J., Wentworth S., Nackley A.G., Maixner W., Diatchenko L.;
RT   "A novel alternatively spliced isoform of the mu-opioid receptor:
RT   functional antagonism.";
RL   Mol. Pain 6:33-33(2010).
RN   [39]
RP   VARIANTS VAL-6; ASP-40 AND CYS-147.
RX   PubMed=9399694; DOI=10.1038/sj.mp.4000331;
RA   Bergen A.W., Kokoszka J., Peterson R., Long J.C., Virkkunen M.,
RA   Linnoila M., Goldman D.;
RT   "Mu opioid receptor gene variants: lack of association with alcohol
RT   dependence.";
RL   Mol. Psychiatry 2:490-494(1997).
RN   [40]
RP   VARIANTS VAL-6; ASP-40 AND HIS-260, CHARACTERIZATION OF VARIANT
RP   ASP-40, POLYMORPHISM, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=9689128; DOI=10.1073/pnas.95.16.9608;
RA   Bond C., LaForge K.S., Tian M., Melia D., Zhang S., Borg L., Gong J.,
RA   Schluger J., Strong J.A., Leal S.M., Tischfield J.A., Kreek M.J.,
RA   Yu L.;
RT   "Single-nucleotide polymorphism in the human mu opioid receptor gene
RT   alters beta-endorphin binding and activity: possible implications for
RT   opiate addiction.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:9608-9613(1998).
CC   -!- FUNCTION: Receptor for endogenous opioids such as beta-endorphin
CC       and endomorphin. Receptor for natural and synthetic opioids
CC       including morphine, heroin, DAMGO, fentanyl, etorphine,
CC       buprenorphin and methadone (PubMed:7905839, PubMed:7957926,
CC       PubMed:7891175, PubMed:12589820, PubMed:9689128). Agonist binding
CC       to the receptor induces coupling to an inactive GDP-bound
CC       heterotrimeric G-protein complex and subsequent exchange of GDP
CC       for GTP in the G-protein alpha subunit leading to dissociation of
CC       the G-protein complex with the free GTP-bound G-protein alpha and
CC       the G-protein beta-gamma dimer activating downstream cellular
CC       effectors (PubMed:7905839). The agonist- and cell type-specific
CC       activity is predominantly coupled to pertussis toxin-sensitive
CC       G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1
CC       isoforms Alpha-1 and Alpha-2, and to a lesser extent to pertussis
CC       toxin-insensitive G alpha proteins GNAZ and GNA15
CC       (PubMed:12068084). They mediate an array of downstream cellular
CC       responses, including inhibition of adenylate cyclase activity and
CC       both N-type and L-type calcium channels, activation of inward
CC       rectifying potassium channels, mitogen-activated protein kinase
CC       (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase
CC       (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-
CC       kappa-B. Also couples to adenylate cyclase stimulatory G alpha
CC       proteins. The selective temporal coupling to G-proteins and
CC       subsequent signaling can be regulated by RGSZ proteins, such as
CC       RGS9, RGS17 and RGS4. Phosphorylation by members of the GPRK
CC       subfamily of Ser/Thr protein kinases and association with beta-
CC       arrestins is involved in short-term receptor desensitization.
CC       Beta-arrestins associate with the GPRK-phosphorylated receptor and
CC       uncouple it from the G-protein thus terminating signal
CC       transduction. The phosphorylated receptor is internalized through
CC       endocytosis via clathrin-coated pits which involves beta-
CC       arrestins. The activation of the ERK pathway occurs either in a G-
CC       protein-dependent or a beta-arrestin-dependent manner and is
CC       regulated by agonist-specific receptor phosphorylation. Acts as a
CC       class A G-protein coupled receptor (GPCR) which dissociates from
CC       beta-arrestin at or near the plasma membrane and undergoes rapid
CC       recycling. Receptor down-regulation pathways are varying with the
CC       agonist and occur dependent or independent of G-protein coupling.
CC       Endogenous ligands induce rapid desensitization, endocytosis and
CC       recycling whereas morphine induces only low desensitization and
CC       endocytosis. Heterooligomerization with other GPCRs can modulate
CC       agonist binding, signaling and trafficking properties. Involved in
CC       neurogenesis. Isoform 12 couples to GNAS and is proposed to be
CC       involved in excitatory effects (PubMed:20525224). Isoform 16 and
CC       isoform 17 do not bind agonists but may act through
CC       oligomerization with binding-competent OPRM1 isoforms and reduce
CC       their ligand binding activity (PubMed:16580639).
CC       {ECO:0000250|UniProtKB:P33535, ECO:0000250|UniProtKB:P42866,
CC       ECO:0000269|PubMed:10529478, ECO:0000269|PubMed:12068084,
CC       ECO:0000269|PubMed:12589820, ECO:0000269|PubMed:16580639,
CC       ECO:0000269|PubMed:20525224, ECO:0000269|PubMed:7891175,
CC       ECO:0000269|PubMed:7905839, ECO:0000269|PubMed:7957926,
CC       ECO:0000269|PubMed:9689128, ECO:0000303|PubMed:10836142,
CC       ECO:0000303|PubMed:19300905}.
CC   -!- SUBUNIT: Forms homooligomers and heterooligomers with other GPCRs,
CC       such as OPRD1, OPRK1, OPRL1, NPFFR2, ADRA2A, SSTR2, CNR1 and CCR5
CC       (probably in dimeric forms) (PubMed:12413885, PubMed:15778451,
CC       PubMed:15967873, PubMed:17224450). Interacts with heterotrimeric G
CC       proteins; interaction with a heterotrimeric complex containing
CC       GNAI1, GNB1 and GNG2 stabilizes the active conformation of the
CC       receptor and increases its affinity for endomorphin-2, the
CC       synthetic opioid peptide DAMGO and for morphinan agonists (By
CC       similarity). Interacts with PPL; the interaction disrupts agonist-
CC       mediated G-protein activation (PubMed:12810704). Interacts (via C-
CC       terminus) with DNAJB4 (via C-terminus) (PubMed:16542645).
CC       Interacts with calmodulin; the interaction inhibits the
CC       constitutive activity of OPRM1; it abolishes basal and attenuates
CC       agonist-stimulated G-protein coupling (PubMed:10419536,
CC       PubMed:10899953). Interacts with FLNA, PLD2, RANBP9 and WLS and
CC       GPM6A (PubMed:12519790, PubMed:14573758, PubMed:19788913,
CC       PubMed:20214800). Interacts with RTP4 (By similarity). Interacts
CC       with SYP and GNAS (By similarity). Interacts with RGS9, RGS17,
CC       RGS20, RGS4, PPP1R9B and HINT1 (By similarity).
CC       {ECO:0000250|UniProtKB:P33535, ECO:0000250|UniProtKB:P42866,
CC       ECO:0000269|PubMed:10419536, ECO:0000269|PubMed:10899953,
CC       ECO:0000269|PubMed:12413885, ECO:0000269|PubMed:12519790,
CC       ECO:0000269|PubMed:12810704, ECO:0000269|PubMed:14573758,
CC       ECO:0000269|PubMed:15778451, ECO:0000269|PubMed:15967873,
CC       ECO:0000269|PubMed:16542645, ECO:0000269|PubMed:17224450,
CC       ECO:0000269|PubMed:19788913, ECO:0000269|PubMed:20214800}.
CC   -!- INTERACTION:
CC       Q9Y679:AUP1; NbExp=4; IntAct=EBI-2624570, EBI-1058701;
CC       Q92905:COPS5; NbExp=5; IntAct=EBI-2624570, EBI-594661;
CC       Q8TEW6:DOK4; NbExp=4; IntAct=EBI-2624570, EBI-6918542;
CC       P21333:FLNA; NbExp=5; IntAct=EBI-2624570, EBI-350432;
CC       P35212:GJA4; NbExp=2; IntAct=EBI-2624570, EBI-6918707;
CC       P01210:PENK; NbExp=3; IntAct=EBI-2624570, EBI-6656055;
CC       Q96S59:RANBP9; NbExp=5; IntAct=EBI-2624570, EBI-636085;
CC       Q8IUQ4:SIAH1; NbExp=4; IntAct=EBI-2624570, EBI-747107;
CC       O43255:SIAH2; NbExp=3; IntAct=EBI-2624570, EBI-948141;
CC       Q9P0L0:VAPA; NbExp=3; IntAct=EBI-2624570, EBI-1059156;
CC       Q5T9L3:WLS; NbExp=10; IntAct=EBI-2624570, EBI-2868748;
CC       Q15942:ZYX; NbExp=2; IntAct=EBI-2624570, EBI-444225;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10529478,
CC       ECO:0000269|PubMed:12589820, ECO:0000269|PubMed:16580639,
CC       ECO:0000269|PubMed:7891175, ECO:0000269|PubMed:7905839,
CC       ECO:0000269|PubMed:7957926, ECO:0000269|PubMed:9689128}; Multi-
CC       pass membrane protein {ECO:0000269|PubMed:16580639}. Cell
CC       projection, axon {ECO:0000250|UniProtKB:P97266}. Perikaryon
CC       {ECO:0000250|UniProtKB:P97266}. Cell projection, dendrite
CC       {ECO:0000250|UniProtKB:P97266}. Endosome
CC       {ECO:0000250|UniProtKB:P97266}. Note=Is rapidly internalized after
CC       agonist binding. {ECO:0000250|UniProtKB:P97266}.
CC   -!- SUBCELLULAR LOCATION: Isoform 12: Cytoplasm
CC       {ECO:0000269|PubMed:20525224}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=18;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1;
CC         IsoId=P35372-1; Sequence=Displayed;
CC       Name=2; Synonyms=MOR1A, MOR-1A;
CC         IsoId=P35372-2; Sequence=VSP_001896;
CC       Name=3; Synonyms=MOR-1R, MOR-1X;
CC         IsoId=P35372-3; Sequence=VSP_037695;
CC         Note=Ref.4 (AAK74189) sequence is in conflict in position:
CC         402:Q->H. {ECO:0000305};
CC       Name=4; Synonyms=MOR-1B3;
CC         IsoId=P35372-4; Sequence=VSP_037696;
CC       Name=5; Synonyms=MOR-1C, MOR-1O;
CC         IsoId=P35372-5; Sequence=VSP_037697;
CC       Name=6; Synonyms=MOR-1V, MOR-1Y, MOR-1Y2, MOR-1Y3;
CC         IsoId=P35372-6; Sequence=VSP_037698;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay.;
CC       Name=7; Synonyms=MOR-1B1;
CC         IsoId=P35372-7; Sequence=VSP_037699;
CC       Name=8; Synonyms=MOR-1B2;
CC         IsoId=P35372-8; Sequence=VSP_037700;
CC       Name=9; Synonyms=MOR-1B5;
CC         IsoId=P35372-9; Sequence=VSP_037701;
CC         Note=Ref.5 (AAQ77392) sequence differs from that shown due to a
CC         polymorphism leading to premature termination of translation
CC         (position: 411:Q->Stop). {ECO:0000305};
CC       Name=10; Synonyms=MOR-1i;
CC         IsoId=P35372-10; Sequence=VSP_037693;
CC       Name=11; Synonyms=MOR-1B4;
CC         IsoId=P35372-11; Sequence=VSP_037694;
CC       Name=12; Synonyms=MOR-1G1, MOR-1K;
CC         IsoId=P35372-12; Sequence=VSP_042327;
CC       Name=13; Synonyms=MOR-1G2;
CC         IsoId=P35372-13; Sequence=VSP_042328;
CC       Name=14; Synonyms=Mu3;
CC         IsoId=P35372-14; Sequence=VSP_042327, VSP_042331;
CC       Name=15; Synonyms=MOR-1W;
CC         IsoId=P35372-15; Sequence=VSP_042327, VSP_001896;
CC       Name=16; Synonyms=SV1;
CC         IsoId=P35372-16; Sequence=VSP_042330;
CC       Name=17; Synonyms=SV2;
CC         IsoId=P35372-17; Sequence=VSP_042329;
CC       Name=18; Synonyms=hMOR-1Z;
CC         IsoId=P35372-18; Sequence=VSP_047577, VSP_047578;
CC   -!- TISSUE SPECIFICITY: Expressed in brain. Isoform 16 and isoform 17
CC       are detected in brain. {ECO:0000269|PubMed:16580639}.
CC   -!- PTM: Phosphorylated. Differentially phosphorylated in basal and
CC       agonist-induced conditions. Agonist-mediated phosphorylation
CC       modulates receptor internalization. Phosphorylated by GRK2 in a
CC       agonist-dependent manner. Phosphorylation at Tyr-168 requires
CC       receptor activation, is dependent on non-receptor protein tyrosine
CC       kinase Src and results in a decrease in agonist efficacy by
CC       reducing G-protein coupling efficiency. Phosphorylated on tyrosine
CC       residues; the phosphorylation is involved in agonist-induced G-
CC       protein-independent receptor down-regulation. Phosphorylation at
CC       Ser-377 is involved in G-protein-dependent but not beta-arrestin-
CC       dependent activation of the ERK pathway (By similarity).
CC       {ECO:0000250|UniProtKB:P33535}.
CC   -!- PTM: Ubiquitinated. A basal ubiquitination seems not to be related
CC       to degradation. Ubiquitination is increased upon formation of
CC       OPRM1:OPRD1 oligomers leading to proteasomal degradation; the
CC       ubiquitination is diminished by RTP4.
CC       {ECO:0000250|UniProtKB:P42866}.
CC   -!- POLYMORPHISM: Variant Asp-40 does not show altered binding
CC       affinities for most opioid peptides and alkaloids tested, but it
CC       binds beta-endorphin, an endogenous opioid that activates the mu
CC       opioid receptor, approximately 3 times more tightly than the most
CC       common allelic form. {ECO:0000269|PubMed:9689128}.
CC   -!- MISCELLANEOUS: OPRM1 is the main physiological target for most
CC       clinically important opioid analgesics. OPRM1-mediated inhibition
CC       of voltage-gated calcium channels on central presynaptic terminals
CC       of primary afferent nociceptors is thought to be one of the
CC       primary mechanisms mediating analgesia at the spinal level.
CC       Opioid-induced hyperalgesic responses are observed following both
CC       acute and chronic dosing associated with cellular excitation.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAI20458.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=EAW47705.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Mu opioid receptor entry;
CC       URL="https://en.wikipedia.org/wiki/Mu_opioid_receptor";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/oprm1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L25119; AAA20580.1; -; mRNA.
DR   EMBL; U12569; AAB60354.1; -; mRNA.
DR   EMBL; L29301; AAA73958.1; -; mRNA.
DR   EMBL; AY036622; AAK74189.1; -; mRNA.
DR   EMBL; AY036623; AAK74190.1; -; mRNA.
DR   EMBL; AY195733; AAO21305.1; -; mRNA.
DR   EMBL; AY225404; AAP44727.1; -; mRNA.
DR   EMBL; AY309001; AAQ77385.1; -; mRNA.
DR   EMBL; AY309005; AAQ77389.1; -; mRNA.
DR   EMBL; AY309006; AAQ77390.1; -; mRNA.
DR   EMBL; AY309007; AAQ77391.1; -; mRNA.
DR   EMBL; AY309008; AAQ77392.1; -; mRNA.
DR   EMBL; AY309009; AAQ77393.1; -; mRNA.
DR   EMBL; EU340241; ACA49726.1; -; mRNA.
DR   EMBL; EU340242; ACA49727.1; -; mRNA.
DR   EMBL; EU340243; ACA49728.1; -; mRNA.
DR   EMBL; AY364230; AAR12887.1; -; mRNA.
DR   EMBL; AY364890; AAR11568.1; -; mRNA.
DR   EMBL; HQ699462; AET97615.1; -; mRNA.
DR   EMBL; EU360599; ABY61366.1; -; mRNA.
DR   EMBL; EU362990; ABY66530.1; -; mRNA.
DR   EMBL; AK313901; BAG36624.1; -; mRNA.
DR   EMBL; AY521028; AAS00462.1; -; mRNA.
DR   EMBL; AY587764; AAS83107.1; -; Genomic_DNA.
DR   EMBL; FJ041292; ACM90350.1; -; mRNA.
DR   EMBL; FJ041293; ACM90351.1; -; mRNA.
DR   EMBL; FJ041294; ACM90352.1; -; mRNA.
DR   EMBL; AL132774; CAI20458.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AL136444; CAI20458.1; JOINED; Genomic_DNA.
DR   EMBL; AL445220; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471051; EAW47705.1; ALT_INIT; Genomic_DNA.
DR   EMBL; BC074927; AAH74927.1; -; mRNA.
DR   EMBL; AY292290; AAP44409.1; -; Genomic_DNA.
DR   EMBL; AY292291; AAP44410.1; -; Genomic_DNA.
DR   EMBL; AF153500; AAD44318.1; -; Genomic_DNA.
DR   CCDS; CCDS43517.1; -. [P35372-5]
DR   CCDS; CCDS43518.1; -. [P35372-3]
DR   CCDS; CCDS47503.1; -. [P35372-10]
DR   CCDS; CCDS47504.1; -. [P35372-7]
DR   CCDS; CCDS47505.1; -. [P35372-8]
DR   CCDS; CCDS47506.1; -. [P35372-4]
DR   CCDS; CCDS47507.1; -. [P35372-9]
DR   CCDS; CCDS47508.1; -. [P35372-2]
DR   CCDS; CCDS55068.1; -. [P35372-13]
DR   CCDS; CCDS55069.1; -. [P35372-11]
DR   CCDS; CCDS55070.1; -. [P35372-1]
DR   CCDS; CCDS55071.1; -. [P35372-12]
DR   PIR; I56553; I56553.
DR   PIR; S65693; S65693.
DR   RefSeq; NP_000905.3; NM_000914.4. [P35372-1]
DR   RefSeq; NP_001008503.2; NM_001008503.2. [P35372-5]
DR   RefSeq; NP_001008504.2; NM_001008504.3. [P35372-2]
DR   RefSeq; NP_001008505.2; NM_001008505.2. [P35372-3]
DR   RefSeq; NP_001138751.1; NM_001145279.3. [P35372-10]
DR   RefSeq; NP_001138752.1; NM_001145280.3. [P35372-12]
DR   RefSeq; NP_001138753.1; NM_001145281.2. [P35372-13]
DR   RefSeq; NP_001138754.1; NM_001145282.2. [P35372-7]
DR   RefSeq; NP_001138755.1; NM_001145283.2. [P35372-8]
DR   RefSeq; NP_001138756.1; NM_001145284.3. [P35372-4]
DR   RefSeq; NP_001138757.1; NM_001145285.2. [P35372-11]
DR   RefSeq; NP_001138758.1; NM_001145286.2. [P35372-9]
DR   RefSeq; NP_001138759.1; NM_001145287.2. [P35372-12]
DR   RefSeq; NP_001272452.1; NM_001285523.2.
DR   RefSeq; NP_001272453.1; NM_001285524.1. [P35372-10]
DR   RefSeq; NP_001272455.1; NM_001285526.1. [P35372-12]
DR   RefSeq; NP_001272456.1; NM_001285527.1. [P35372-15]
DR   RefSeq; NP_001272457.1; NM_001285528.2. [P35372-14]
DR   RefSeq; XP_016866395.1; XM_017010906.1. [P35372-12]
DR   UniGene; Hs.2353; -.
DR   ProteinModelPortal; P35372; -.
DR   SMR; P35372; -.
DR   BioGrid; 111033; 73.
DR   IntAct; P35372; 58.
DR   MINT; MINT-100121; -.
DR   STRING; 9606.ENSP00000394624; -.
DR   BindingDB; P35372; -.
DR   ChEMBL; CHEMBL233; -.
DR   DrugBank; DB01571; 3-Methylfentanyl.
DR   DrugBank; DB01439; 3-Methylthiofentanyl.
DR   DrugBank; DB00802; Alfentanil.
DR   DrugBank; DB06274; Alvimopan.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB00913; Anileridine.
DR   DrugBank; DB00921; Buprenorphine.
DR   DrugBank; DB00611; Butorphanol.
DR   DrugBank; DB01535; Carfentanil.
DR   DrugBank; DB00318; Codeine.
DR   DrugBank; DB00514; Dextromethorphan.
DR   DrugBank; DB00647; Dextropropoxyphene.
DR   DrugBank; DB01209; Dezocine.
DR   DrugBank; DB01565; Dihydromorphine.
DR   DrugBank; DB01444; Dimethylthiambutene.
DR   DrugBank; DB01081; Diphenoxylate.
DR   DrugBank; DB01548; Diprenorphine.
DR   DrugBank; DB09272; Eluxadoline.
DR   DrugBank; DB05492; Epicept NP-1.
DR   DrugBank; DB01466; Ethylmorphine.
DR   DrugBank; DB01497; Etorphine.
DR   DrugBank; DB00813; Fentanyl.
DR   DrugBank; DB01452; Heroin.
DR   DrugBank; DB00956; Hydrocodone.
DR   DrugBank; DB00327; Hydromorphone.
DR   DrugBank; DB01221; Ketamine.
DR   DrugBank; DB06738; Ketobemidone.
DR   DrugBank; DB00504; Levallorphan.
DR   DrugBank; DB01227; Levomethadyl Acetate.
DR   DrugBank; DB00854; Levorphanol.
DR   DrugBank; DB05509; LI-301.
DR   DrugBank; DB00836; Loperamide.
DR   DrugBank; DB00333; Methadone.
DR   DrugBank; DB01433; Methadyl Acetate.
DR   DrugBank; DB06800; Methylnaltrexone.
DR   DrugBank; DB00295; Morphine.
DR   DrugBank; DB00844; Nalbuphine.
DR   DrugBank; DB09049; Naloxegol.
DR   DrugBank; DB01183; Naloxone.
DR   DrugBank; DB00704; Naltrexone.
DR   DrugBank; DB00904; Ondansetron.
DR   DrugBank; DB00497; Oxycodone.
DR   DrugBank; DB01192; Oxymorphone.
DR   DrugBank; DB00652; Pentazocine.
DR   DrugBank; DB00454; Pethidine.
DR   DrugBank; DB00899; Remifentanil.
DR   DrugBank; DB00708; Sufentanil.
DR   DrugBank; DB06204; Tapentadol.
DR   DrugBank; DB00193; Tramadol.
DR   DrugBank; DB05046; V1003.
DR   GuidetoPHARMACOLOGY; 319; -.
DR   TCDB; 9.A.14.13.18; the g-protein-coupled receptor (gpcr) family.
DR   iPTMnet; P35372; -.
DR   PhosphoSitePlus; P35372; -.
DR   SwissPalm; P35372; -.
DR   BioMuta; OPRM1; -.
DR   DMDM; 2851402; -.
DR   PaxDb; P35372; -.
DR   PeptideAtlas; P35372; -.
DR   PRIDE; P35372; -.
DR   Ensembl; ENST00000229768; ENSP00000229768; ENSG00000112038. [P35372-3]
DR   Ensembl; ENST00000330432; ENSP00000328264; ENSG00000112038. [P35372-1]
DR   Ensembl; ENST00000337049; ENSP00000338381; ENSG00000112038. [P35372-5]
DR   Ensembl; ENST00000414028; ENSP00000399359; ENSG00000112038. [P35372-4]
DR   Ensembl; ENST00000419506; ENSP00000403549; ENSG00000112038. [P35372-9]
DR   Ensembl; ENST00000428397; ENSP00000411903; ENSG00000112038. [P35372-2]
DR   Ensembl; ENST00000434900; ENSP00000394624; ENSG00000112038. [P35372-10]
DR   Ensembl; ENST00000435918; ENSP00000413752; ENSG00000112038. [P35372-8]
DR   Ensembl; ENST00000452687; ENSP00000410497; ENSG00000112038. [P35372-7]
DR   Ensembl; ENST00000518759; ENSP00000430260; ENSG00000112038. [P35372-13]
DR   Ensembl; ENST00000519083; ENSP00000431048; ENSG00000112038. [P35372-6]
DR   Ensembl; ENST00000520708; ENSP00000430876; ENSG00000112038. [P35372-12]
DR   Ensembl; ENST00000522236; ENSP00000429373; ENSG00000112038. [P35372-12]
DR   Ensembl; ENST00000522555; ENSP00000429719; ENSG00000112038. [P35372-12]
DR   Ensembl; ENST00000522739; ENSP00000428018; ENSG00000112038. [P35372-6]
DR   Ensembl; ENST00000524150; ENSP00000430575; ENSG00000112038. [P35372-18]
DR   Ensembl; ENST00000524163; ENSP00000430097; ENSG00000112038. [P35372-11]
DR   GeneID; 4988; -.
DR   KEGG; hsa:4988; -.
DR   UCSC; uc003qpn.4; human. [P35372-1]
DR   CTD; 4988; -.
DR   DisGeNET; 4988; -.
DR   GeneCards; OPRM1; -.
DR   HGNC; HGNC:8156; OPRM1.
DR   HPA; HPA014509; -.
DR   HPA; HPA067435; -.
DR   MalaCards; OPRM1; -.
DR   MIM; 600018; gene.
DR   neXtProt; NX_P35372; -.
DR   OpenTargets; ENSG00000112038; -.
DR   PharmGKB; PA31945; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   eggNOG; ENOG410XRW9; LUCA.
DR   GeneTree; ENSGT00760000118797; -.
DR   HOGENOM; HOG000230486; -.
DR   HOVERGEN; HBG106919; -.
DR   InParanoid; P35372; -.
DR   KO; K04215; -.
DR   OMA; NSTRVRQ; -.
DR   OrthoDB; EOG091G0HEN; -.
DR   PhylomeDB; P35372; -.
DR   TreeFam; TF315737; -.
DR   Reactome; R-HSA-111885; Opioid Signalling.
DR   Reactome; R-HSA-202040; G-protein activation.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-6785807; Interleukin-4 and 13 signaling.
DR   SIGNOR; P35372; -.
DR   GeneWiki; %CE%9C-opioid_receptor; -.
DR   GenomeRNAi; 4988; -.
DR   PRO; PR:P35372; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000112038; -.
DR   CleanEx; HS_OPRM1; -.
DR   ExpressionAtlas; P35372; baseline and differential.
DR   Genevisible; P35372; HS.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0005623; C:cell; IEA:GOC.
DR   GO; GO:0030425; C:dendrite; ISS:UniProtKB.
DR   GO; GO:0032839; C:dendrite cytoplasm; IEA:Ensembl.
DR   GO; GO:0032590; C:dendrite membrane; IEA:Ensembl.
DR   GO; GO:0005783; C:endoplasmic reticulum; TAS:ProtInc.
DR   GO; GO:0005768; C:endosome; ISS:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IEA:Ensembl.
DR   GO; GO:0005794; C:Golgi apparatus; TAS:ProtInc.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0043204; C:perikaryon; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0098794; C:postsynapse; IEA:GOC.
DR   GO; GO:0042383; C:sarcolemma; IEA:Ensembl.
DR   GO; GO:0004979; F:beta-endorphin receptor activity; IMP:UniProtKB.
DR   GO; GO:0001965; F:G-protein alpha-subunit binding; IDA:UniProtKB.
DR   GO; GO:0031681; F:G-protein beta-subunit binding; IBA:GO_Central.
DR   GO; GO:0004930; F:G-protein coupled receptor activity; ISS:UniProtKB.
DR   GO; GO:0038047; F:morphine receptor activity; ISS:UniProtKB.
DR   GO; GO:0042923; F:neuropeptide binding; IBA:GO_Central.
DR   GO; GO:0005245; F:voltage-gated calcium channel activity; ISS:UniProtKB.
DR   GO; GO:0002438; P:acute inflammatory response to antigenic stimulus; IEA:Ensembl.
DR   GO; GO:0007191; P:adenylate cyclase-activating dopamine receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0031635; P:adenylate cyclase-inhibiting opioid receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0048149; P:behavioral response to ethanol; IMP:UniProtKB.
DR   GO; GO:0071315; P:cellular response to morphine; IBA:GO_Central.
DR   GO; GO:0033554; P:cellular response to stress; IMP:UniProtKB.
DR   GO; GO:0007268; P:chemical synaptic transmission; IBA:GO_Central.
DR   GO; GO:0042755; P:eating behavior; IEA:Ensembl.
DR   GO; GO:0044849; P:estrous cycle; IEA:Ensembl.
DR   GO; GO:0060079; P:excitatory postsynaptic potential; IEA:Ensembl.
DR   GO; GO:0007187; P:G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; TAS:ProtInc.
DR   GO; GO:0007626; P:locomotory behavior; IEA:Ensembl.
DR   GO; GO:0007194; P:negative regulation of adenylate cyclase activity; ISS:UniProtKB.
DR   GO; GO:0043951; P:negative regulation of cAMP-mediated signaling; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:0051481; P:negative regulation of cytosolic calcium ion concentration; IDA:UniProtKB.
DR   GO; GO:0045019; P:negative regulation of nitric oxide biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0061358; P:negative regulation of Wnt protein secretion; IMP:UniProtKB.
DR   GO; GO:0038003; P:opioid receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007200; P:phospholipase C-activating G-protein coupled receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0032100; P:positive regulation of appetite; IEA:Ensembl.
DR   GO; GO:0043950; P:positive regulation of cAMP-mediated signaling; IDA:UniProtKB.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IDA:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0050769; P:positive regulation of neurogenesis; ISS:UniProtKB.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IDA:UniProtKB.
DR   GO; GO:2000310; P:regulation of NMDA receptor activity; ISS:UniProtKB.
DR   GO; GO:0051930; P:regulation of sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0042220; P:response to cocaine; IEA:Ensembl.
DR   GO; GO:0032094; P:response to food; IEA:Ensembl.
DR   GO; GO:0070848; P:response to growth factor; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0009314; P:response to radiation; IEA:Ensembl.
DR   GO; GO:0007600; P:sensory perception; NAS:UniProtKB.
DR   GO; GO:0019233; P:sensory perception of pain; ISS:UniProtKB.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR000105; Mu_opioid_rcpt.
DR   InterPro; IPR001418; Opioid_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00537; MUOPIOIDR.
DR   PRINTS; PR00384; OPIOIDR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Cell projection;
KW   Complete proteome; Cytoplasm; Disulfide bond; Endosome;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane;
KW   Palmitate; Phosphoprotein; Polymorphism; Receptor; Reference proteome;
KW   Transducer; Transmembrane; Transmembrane helix; Ubl conjugation.
FT   CHAIN         1    400       Mu-type opioid receptor.
FT                                /FTId=PRO_0000069972.
FT   TOPO_DOM      1     68       Extracellular.
FT                                {ECO:0000250|UniProtKB:P42866}.
FT   TRANSMEM     69     93       Helical; Name=1.
FT                                {ECO:0000250|UniProtKB:P42866}.
FT   TOPO_DOM     94    106       Cytoplasmic.
FT                                {ECO:0000250|UniProtKB:P42866}.
FT   TRANSMEM    107    131       Helical; Name=2.
FT                                {ECO:0000250|UniProtKB:P42866}.
FT   TOPO_DOM    132    142       Extracellular.
FT                                {ECO:0000250|UniProtKB:P42866}.
FT   TRANSMEM    143    165       Helical; Name=3.
FT                                {ECO:0000250|UniProtKB:P42866}.
FT   TOPO_DOM    166    185       Cytoplasmic.
FT                                {ECO:0000250|UniProtKB:P42866}.
FT   TRANSMEM    186    207       Helical; Name=4.
FT                                {ECO:0000250|UniProtKB:P42866}.
FT   TOPO_DOM    208    230       Extracellular.
FT                                {ECO:0000250|UniProtKB:P42866}.
FT   TRANSMEM    231    255       Helical; Name=5.
FT                                {ECO:0000250|UniProtKB:P42866}.
FT   TOPO_DOM    256    279       Cytoplasmic.
FT                                {ECO:0000250|UniProtKB:P42866}.
FT   TRANSMEM    280    306       Helical; Name=6.
FT                                {ECO:0000250|UniProtKB:P42866}.
FT   TOPO_DOM    307    314       Extracellular.
FT                                {ECO:0000250|UniProtKB:P42866}.
FT   TRANSMEM    315    338       Helical; Name=7.
FT                                {ECO:0000250|UniProtKB:P42866}.
FT   TOPO_DOM    339    400       Cytoplasmic.
FT                                {ECO:0000250|UniProtKB:P42866}.
FT   MOTIF       334    338       NPxxY; plays a role in stabilizing the
FT                                activated conformation of the receptor.
FT                                {ECO:0000250|UniProtKB:P42866}.
FT   MOD_RES     168    168       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P33535}.
FT   MOD_RES     365    365       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P42866}.
FT   MOD_RES     372    372       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P33535}.
FT   MOD_RES     377    377       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P33535}.
FT   LIPID       353    353       S-palmitoyl cysteine. {ECO:0000255}.
FT   CARBOHYD      9      9       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     12     12       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     33     33       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     40     40       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     48     48       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    142    219       {ECO:0000255|PROSITE-ProRule:PRU00521}.
FT   VAR_SEQ       1    100       Missing (in isoform 12, isoform 14 and
FT                                isoform 15).
FT                                {ECO:0000303|PubMed:12734358,
FT                                ECO:0000303|PubMed:19077058,
FT                                ECO:0000303|PubMed:19103668,
FT                                ECO:0000303|Ref.8}.
FT                                /FTId=VSP_042327.
FT   VAR_SEQ       1     96       MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNL
FT                                SDPCGPNRTDLGGRDSLCPPTGSPSMITAITIMALYSIVCV
FT                                VGLFGNFLVMYVIV -> MMRAKSISTKAGKPS (in
FT                                isoform 13).
FT                                {ECO:0000303|PubMed:19077058}.
FT                                /FTId=VSP_042328.
FT   VAR_SEQ       1      1       M -> MCLHRRVPSEETYSLDRFAQNPPLFPPPSLPASESR
FT                                MAHAPLLQRCGAARTGFCKKQQELWQRRKEAAEALGTRKVS
FT                                VLLATSHSGARPAVSTM (in isoform 10).
FT                                {ECO:0000303|PubMed:19077058,
FT                                ECO:0000303|Ref.14}.
FT                                /FTId=VSP_037693.
FT   VAR_SEQ      97    400       RYTKMKTATNIYIFNLALADALATSTLPFQSVNYLMGTWPF
FT                                GTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKAL
FT                                DFRTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDC
FT                                TLTFSHPTWYWENLLKICVFIFAFIMPVLIITVCYGLMILR
FT                                LKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHIY
FT                                VIIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLD
FT                                ENFKRCFREFCIPTSSNIEQQNSTRIRQNTRDHPSTANTVD
FT                                RTNHQLENLEAETAPLP -> SSSWF (in isoform
FT                                17). {ECO:0000305}.
FT                                /FTId=VSP_042329.
FT   VAR_SEQ      98    400       YTKMKTATNIYIFNLALADALATSTLPFQSVNYLMGTWPFG
FT                                TILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALD
FT                                FRTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDCT
FT                                LTFSHPTWYWENLLKICVFIFAFIMPVLIITVCYGLMILRL
FT                                KSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHIYV
FT                                IIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDE
FT                                NFKRCFREFCIPTSSNIEQQNSTRIRQNTRDHPSTANTVDR
FT                                TNHQLENLEAETAPLP -> YSWFVIGGPEGRRKQRRLGED
FT                                KRARGCGEKG (in isoform 16).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_042330.
FT   VAR_SEQ      98    186       YTKMKTATNIYIFNLALADALATSTLPFQSVNYLMGTWPFG
FT                                TILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALD
FT                                FRTPRNA -> FHRLYTNILSSNLVLGKPAEDLCFHLRLHY
FT                                ASAHHYRVLWTDDLAPQECPHALWLQRKGQESSKDHQDGAG
FT                                GGGCVHRLLDSHSHLRHH (in isoform 18).
FT                                {ECO:0000303|Ref.9}.
FT                                /FTId=VSP_047577.
FT   VAR_SEQ     187    400       Missing (in isoform 18).
FT                                {ECO:0000303|Ref.9}.
FT                                /FTId=VSP_047578.
FT   VAR_SEQ     389    400       LENLEAETAPLP -> S (in isoform 11).
FT                                {ECO:0000303|PubMed:15893644}.
FT                                /FTId=VSP_037694.
FT   VAR_SEQ     389    400       LENLEAETAPLP -> NYYIIHRCCCNTPLISQKPVLLWFC
FT                                D (in isoform 14).
FT                                {ECO:0000303|PubMed:12734358}.
FT                                /FTId=VSP_042331.
FT   VAR_SEQ     389    400       LENLEAETAPLP -> VRSL (in isoform 2 and
FT                                isoform 15).
FT                                {ECO:0000303|PubMed:15893644,
FT                                ECO:0000303|PubMed:7957926,
FT                                ECO:0000303|Ref.8}.
FT                                /FTId=VSP_001896.
FT   VAR_SEQ     389    400       LENLEAETAPLP -> CLPIPSLSCWALEQGCLVVYPGPLQ
FT                                GPLVRYDLPAILHSSCLRGNTAPSPSGGAFLLS (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:12589820}.
FT                                /FTId=VSP_037695.
FT   VAR_SEQ     389    400       LENLEAETAPLP -> GPPAKFVADQLAGSS (in
FT                                isoform 4).
FT                                {ECO:0000303|PubMed:15893644}.
FT                                /FTId=VSP_037696.
FT   VAR_SEQ     389    400       LENLEAETAPLP -> PPLAVSMAQIFTRYPPPTHREKTCN
FT                                DYMKR (in isoform 5).
FT                                {ECO:0000303|PubMed:12589820}.
FT                                /FTId=VSP_037697.
FT   VAR_SEQ     389    400       LENLEAETAPLP -> IRDPISNLPRVSVF (in
FT                                isoform 6). {ECO:0000303|PubMed:15893644,
FT                                ECO:0000303|Ref.14, ECO:0000303|Ref.8}.
FT                                /FTId=VSP_037698.
FT   VAR_SEQ     389    400       LENLEAETAPLP -> KIDLFQKSSLLNCEHTKG (in
FT                                isoform 7).
FT                                {ECO:0000303|PubMed:15893644}.
FT                                /FTId=VSP_037699.
FT   VAR_SEQ     389    400       LENLEAETAPLP -> RERRQKSDW (in isoform 8).
FT                                {ECO:0000303|PubMed:15893644}.
FT                                /FTId=VSP_037700.
FT   VAR_SEQ     389    400       LENLEAETAPLP -> VELNLDCHCENAKPWPLSYNAGQSP
FT                                FPFPGRV (in isoform 9).
FT                                {ECO:0000303|PubMed:15893644}.
FT                                /FTId=VSP_037701.
FT   VARIANT       6      6       A -> V (in dbSNP:rs1799972).
FT                                {ECO:0000269|PubMed:9399694,
FT                                ECO:0000269|PubMed:9689128,
FT                                ECO:0000269|Ref.13, ECO:0000269|Ref.18}.
FT                                /FTId=VAR_009525.
FT   VARIANT      40     40       N -> D (in 10% of the population;
FT                                dbSNP:rs1799971).
FT                                {ECO:0000269|PubMed:7957926,
FT                                ECO:0000269|PubMed:9399694,
FT                                ECO:0000269|PubMed:9689128,
FT                                ECO:0000269|Ref.13}.
FT                                /FTId=VAR_009524.
FT   VARIANT      63     63       G -> V (in dbSNP:rs9282817).
FT                                /FTId=VAR_049426.
FT   VARIANT      66     66       S -> F (in dbSNP:rs9282819).
FT                                /FTId=VAR_049427.
FT   VARIANT     147    147       S -> C (rare polymorphism;
FT                                dbSNP:rs17174794).
FT                                {ECO:0000269|PubMed:9399694,
FT                                ECO:0000269|Ref.13}.
FT                                /FTId=VAR_009526.
FT   VARIANT     152    152       N -> D (in dbSNP:rs17174801).
FT                                {ECO:0000269|Ref.13}.
FT                                /FTId=VAR_019252.
FT   VARIANT     260    260       R -> H (rare polymorphism;
FT                                dbSNP:rs1799974).
FT                                {ECO:0000269|PubMed:9689128}.
FT                                /FTId=VAR_009527.
FT   VARIANT     265    265       R -> C (in dbSNP:rs17174822).
FT                                {ECO:0000269|Ref.13}.
FT                                /FTId=VAR_019253.
FT   VARIANT     274    274       D -> N (in dbSNP:rs17174829).
FT                                {ECO:0000269|Ref.13}.
FT                                /FTId=VAR_019254.
FT   MUTAGEN     142    142       C->A,S: Abolishes ligand binding; when
FT                                associated with A-219 or S-219.
FT                                {ECO:0000269|PubMed:10529478}.
FT   MUTAGEN     219    219       C->A,S: Abolishes ligand binding; when
FT                                associated with A-142 or S-142.
FT                                {ECO:0000269|PubMed:10529478}.
FT   MUTAGEN     273    273       K->A: Impairs interaction with
FT                                calmodulin. {ECO:0000269|PubMed:10419536,
FT                                ECO:0000269|PubMed:10899953}.
FT   MUTAGEN     275    275       R->A: Impairs interaction with
FT                                calmodulin.
FT                                {ECO:0000269|PubMed:10899953}.
FT   CONFLICT     26     26       P -> L (in Ref. 11; BAG36624).
FT                                {ECO:0000305}.
FT   CONFLICT     51     51       D -> N (in Ref. 1; AAA20580).
FT                                {ECO:0000305}.
FT   CONFLICT    109    109       I -> V (in Ref. 6; AAQ77391).
FT                                {ECO:0000305}.
FT   CONFLICT    207    207       M -> I (in Ref. 2; AAB60354).
FT                                {ECO:0000305}.
FT   CONFLICT    234    234       L -> V (in Ref. 1; AAA20580).
FT                                {ECO:0000305}.
SQ   SEQUENCE   400 AA;  44779 MW;  1DABEBEC9AFF6F66 CRC64;
     MDSSAAPTNA SNCTDALAYS SCSPAPSPGS WVNLSHLDGN LSDPCGPNRT DLGGRDSLCP
     PTGSPSMITA ITIMALYSIV CVVGLFGNFL VMYVIVRYTK MKTATNIYIF NLALADALAT
     STLPFQSVNY LMGTWPFGTI LCKIVISIDY YNMFTSIFTL CTMSVDRYIA VCHPVKALDF
     RTPRNAKIIN VCNWILSSAI GLPVMFMATT KYRQGSIDCT LTFSHPTWYW ENLLKICVFI
     FAFIMPVLII TVCYGLMILR LKSVRMLSGS KEKDRNLRRI TRMVLVVVAV FIVCWTPIHI
     YVIIKALVTI PETTFQTVSW HFCIALGYTN SCLNPVLYAF LDENFKRCFR EFCIPTSSNI
     EQQNSTRIRQ NTRDHPSTAN TVDRTNHQLE NLEAETAPLP
//
